Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip
Eli Lilly and Co LLY
$1,184.63
▼ -0.01%
($-0.15)
Index member:
S&P 500
Open
$1,186.05
Prev Close
$1,184.78
Day Range
$1,168.47 – $1,192.94
52W Range
$716.08 – $1,292.65
Market Cap
$1.11T
P/E (TTM)
41.63
Beta
0.43
Div Yield
0.75%
EPS (TTM)
$29.80
📋 Company Profile
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 1970-07-09 |
| Shares Out. | 941,740,000 |
| Website | lilly.com/ ↗ |
| Phone | 13172762000 |
| Employees | 50,000 |
| Revenue | $22.97B |
| Gross Profit | $19.71B |
| Net Income | $7.10B |
| Free Cash Flow | $18.19B |
| Total Assets | $142.28B |
| Total Liabilities | $108.40B |
| Equity | $33.88B |
About Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly and Co is a publicly traded company under the ticker symbol LLY on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
38 analysts (2026-09-01)
📰 Latest News for LLY
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
Eli Lilly CEO delivers stark message on what comes next
Is Eli Lilly Stock a Good Fit For Your Portfolio Risk?
Eli Lilly Shares Rise After Foundayo Shows More Weight Loss
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy